OncoMatch/Clinical Trials/NCT03379909
Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer
Is NCT03379909 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Metformin for superficial bladder cancer.
Treatment: Metformin — A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a index papillary NMIBC tumour.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Urothelial Carcinoma
Disease stage
Grade: g1g2
Performance status
ECOG-WHO 0–2
Prior therapy
Cannot have received: intravesical chemotherapy
Patients who have received intravesical treatment (chemotherapy or immunotherapy) within the last 3 months.
Cannot have received: intravesical immunotherapy
Patients who have received intravesical treatment (chemotherapy or immunotherapy) within the last 3 months.
Cannot have received: anti-cancer therapy
Patients that are currently receiving other anti-cancer therapy.
Lab requirements
Kidney function
egfr >50 ml/min/1.73m2 according to ckd-epi
Liver function
bilirubin <1.5 times upper limit of normal, alat or asat <2.5 the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03379909 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior intravesical chemotherapy, intravesical immunotherapy, anti-cancer therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages